2025
Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast cancer and its potential clinical implications
Wang J, Katsaros D, Wang Z, Ma L, Casetta E, Fei P, Denti P, Grimaudo I, Chen S, Deng Y, Yu H. Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast cancer and its potential clinical implications. Breast Cancer Research And Treatment 2025, 211: 675-685. PMID: 40102335, DOI: 10.1007/s10549-025-07682-x.Peer-Reviewed Original ResearchConceptsBreast tumorsInvolvement of tRNARegulation of cell phenotypeSuppress breast cancer progressionSmall non-coding RNAsIn silico analysisOncogenic transcription factorHormone receptor statusCox proportional hazards regressionMitochondrial tRNAsBreast cancer progressionCleaves tRNATRNA fragmentsProportional hazards regressionRNase 4Non-coding RNAsPotential clinical implicationsResting mast cellsTranscription factorsSilico analysisReceptor statusTumor immunityQuantitative RT-PCRTRNATumor grade
2013
Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers
Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers. PLOS ONE 2013, 8: e81408. PMID: 24282590, PMCID: PMC3839880, DOI: 10.1371/journal.pone.0081408.Peer-Reviewed Original ResearchConceptsLung adenocarcinomaOverall survivalFemale patientsMiR-195MiR-122Survival outcomesPlasma levelsEGFR statusNon-smoking female patientsCox proportional hazards regressionKaplan-Meier survival analysisEGFR-mutant patientsProportional hazards regressionAdvanced disease stageEGFR mutation statusTime-dependent receiverMiR-122 expressionReal-time RT-PCRHazards regressionPoor prognosisPrognostic valueDisease stageNon smokersMutant patientsEGFR mutations
2005
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.Peer-Reviewed Original ResearchConceptsOvarian cancer treatmentDisease progressionGSTP1 genotypesGST polymorphismsPrimary epithelial ovarian cancerCox proportional hazards regressionFunctional polymorphismsGSTP1 Ile/IleCancer treatmentGSTP1 Ile/ValGlutathione S-transferase polymorphismsGSTM1 null patientsPost-operative chemotherapySubgroup of patientsProportional hazards regressionEpithelial ovarian cancerOvarian cancer survivalEffect of chemotherapyOvarian cancer prognosisOvarian cancer progressionVal/ValIle/IleIle/ValOverall survivalTumor characteristics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply